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Abstract To determine self-reported health status in
non-dystrophic myotonias (NDM) and its relationship to
painful myotonia and fatigue. In a cross-sectional study, 32
NDM patients with chloride and 30 with sodium channel-
opathies, all off treatment, completed a standardised
interview, the fatigue assessment scale (FAS), and the 36-
item Short-Form Health Survey (SF-36). Beside formal
assessment of pain, assessment of painful or painless
myotonia was determined. The domain scores of the SF-36
were compared with Dutch community scores. Apart from
the relationship among SF-36 scores and (1) painful
myotonia and (2) fatigue, regression analyses in both NDM
groups were conducted to determine the strongest deter-
minants of the SF-36 domains general health perception,
physical component (PCS) and mental component sum-
mary (MCS). All physically oriented SF-36 domains in
both NDM groups (P B 0.01) and social functioning in the
patients with sodium channelopathies (P = 0.048) were
substantially lower relative to the Dutch community scores.
The patients with painful myotonia (41.9%) scored sub-
stantially (P\0.05) lower on most SF-36 domains than
the patients without painful myotonia (58.1%). Fatigued
patients (53.2%) scored substantially lower (P B 0.01) on
all SF-36 domains than their non-fatigued counterparts
(46.8%). The regression analysis showed that fatigue was
the strongest predictor for the general-health perception
and painful myotonia for the physical-component sum-
mary. None of the patients showed below-norm scores on
the domain mental-component summary. The impact of
NDM on the physical domains of patients’ health status is
substantial, and particularly painful myotonia and fatigue
tend to impede their physical functioning.
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Introduction
Non-dystrophic myotonias (NDM) are caused by mutations
in genes encoding the skeletal muscle chloride (CLCN1)o r
sodium channel (SCN4A). Mutations in CLCN1 are
responsible for recessive and dominant myotonia congenita
(recessive MC [MIM 160800] and dominant MC
[255700]), and mutations in SCN4A for paramyotonia
congenita (PC [MIM 168300]) and potassium-aggravated
myotonias (PAM [MIM 608390]) [29].
The key symptom of MC is myotonia, and especially
patients with recessive MC show a combination with
transient paresis [4]. Both symptoms improve with
continuing exercise, which is referred to as the warm-up
phenomenon [9, 26]. Conversely, in PC myotonia worsens
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observed in PC and is mostly elicited by cold or prolonged
exercise [10]. Myotonia in PAM is clinically characterised
by unusual features such as temporal ﬂuctuation (myotonia
ﬂuctuans), permanent myotonia (myotonia permanens) or
acetazolamide-responsive myotonia (acetazolamide-
responsive myotonia congenita) [19, 27, 35].
Myotonia in NDM is often described as painless muscle
stiffness [12]. However, Becker found 15% of his patients
with recessive MC to report pain complaints [4]. Also, a
ﬂuctuating form of dominant MC, acetazolamide-respon-
sive myotonia congenita and the V445M sodium channel
mutation were all associated with painful myotonia; thus,
pain appears to be a recurrent symptom in NDM. [4, 28, 35,
37].
Another symptom in neuromuscular diseases is fatigue.
Although initially underreported in neuromuscular disor-
ders, fatigue has now been established in post-polio
syndrome, immune-mediated polyneuropathies, myasthe-
nia gravis, facioscapulohumeral muscular dystrophy,
myotonic dystrophy, and type-I hereditary motor and sen-
sory neuropathy [5, 15, 20, 24, 32]. Our clinical experience
has taught us that also patients with NDM may complain of
fatigue.
Despite their symptoms and signs, NDMs are considered
to be ‘‘benign diseases’’ with possible inﬂuences on the
patients’ ability to perform activities of daily living,
affecting their social participation [18]. This explains why
to date no clinical reports are available that have system-
atically examined the effects NDM has on the patients’
health status, where health status is deﬁned as the impact of
the disease on a patient’s physical, psychological and social
functioning [6]. The presence of painful myotonia and
fatigue in patients with NDM and their impact on the
patients’ health status has likewise not been systematically
investigated. Therefore, we investigated the impact of
NDM on health status. We additionally examined the
presence and effects of painful myotonia and fatigue and,
ﬁnally, performed regression analyses to investigate the
contribution of various determinants assumed to impair the
patients’ physical, psychological and social functioning.
Patients and methods
Patients
In March 2005 neurologists across The Netherlands as well
as the VSN, the Dutch patient association for neuromus-
cular diseases, were requested to report all patients with a
clinical suspicion of NDM to our research group for a full
year. Inclusion criteria were age (C18 years), a diagnosis
of NDM according to established clinical criteria and
needle-EMG evidence of myotonic discharges [17].
Exclusion criteria were a clinical or genetic diagnosis of
type-1 or type-2 myotonic dystrophy or primary periodic
paralysis, serious co-morbidity, unwillingness or inability
to reduce or stop drug therapy for myotonia during the
study and no detectable mutations in CLCN1 or SCN4A.
The 1-year recruitment period yielded a total of 97
potentially eligible patients. Nine patients were unable to
participate due to transportation problems. Based on the
selection criteria, another 26 patients were excluded: 7 had
a primary periodic paralysis, 12 serious co-morbidity, 5
were unwilling to reduce and stop myotonia-related drug
therapy, and 2 did not present clinical signs of myotonia
and lacked myotonic discharges (needle-EMG). All
remaining 62 patients demonstrated DNA mutations in
either CLCN1 (n = 32) or SCN4A (n = 30) [33, 34]. The
study was approved by the Medical Ethics Committee of
the Radboud University Nijmegen Medical Centre, and all
patients gave their written informed consent prior to their
participation.
Examination procedures
Standardised interview
With the standardised interview the following characteris-
tics of all NDM patients were established: age, gender,
duration of symptoms, frequency, pattern (reduction or
augmentation of myotonia after repetitive movements) and
severity of the myotonia [Numerical Rating Scale (NRS),
range 1–10; 1 means almost no myotonia and 10 means
very serious myotonia], changes in severity, presence of
muscle weakness, presence of painful or painless myotonia
and eventually the severity of the painful myotonia (NRS,
range 1–10, 1 means almost no painful myotonia and 10
means very serious painful myotonia).
Painful myotonia
We used the outcome of the standardised interview to di-
chotomise patients with painless and those with painful
myotonia. Patients with painful myotonia were also asked
about the severity of their pain (NRS, range 1–10).
Fatigue assessment scale
Fatigue was assessed with the ten-item self-reported
fatigue assessment scale (FAS) [21]. Five items probe
physical and ﬁve mental fatigue. Each item is scored on
a 5-point Likert scale with the total score ranging from
10 to 50. Higher scores indicate higher fatigue levels.
The scale’s validity and reliability of the FAS were good
[7, 8, 21]. We took FAS scores equal to or higher than
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12322 to be indicative of fatigue and used this as the cutoff
score to dichotomise fatigued and non-fatigued NDM
patients [8].
Short-Form 36-Item Health Survey
Patients completed the Short-Form 36-Item Health Status
Survey (SF-36, Dutch version), a generic questionnaire to
establish patients’ self-reported health status [1, 38]. It
appraises the following domains: physical functioning
(ten items), role functioning physical (4), role functioning
emotional (3), social functioning (2), body pain (2),
mental health (5), vitality (4), general-health perception
(5), and change in health, which is scored separately [38].
The number of response categories per item ranges from
two to six. Each domain has a scoring range of 0–100
with higher scores, indicating better health or functioning
and less body pain. The scale’s physical component
summary (PCS) and mental component summary (MCS)
scores were also calculated using the reported means,
standard deviations and factor-score coefﬁcients derived
from the general Dutch population [1, 38–40]. The PCS
captures the individual’s overall physical functioning by
considering reported limitations in care, physical, social
and role activities, amount of pain, and level of energy.
The MCS reﬂects the respondent’s overall mental func-
tioning by considering the frequency of psychological
distress and limitations in usual social and role activities
due to emotional problems [39]. A linear T score trans-
formation method was used so that the PCS had a mean
of 49.7 (SD 9.3), and the MCS had a mean of 52.1 (SD
9.6), as reported for the general Dutch population [1, 38–
40]. The SF-36 has been shown to have a good validity
and reliability [1, 38–40]. For our comparative analyses,
we used the reported mean (SD) SF-36 domain scores of
a random, Dutch nationwide sample of 1,742 healthy
individuals consisting of 976 men and 766 women with a
mean age of 47.6 years (18.0 years; range 16–94 years)
[1, 40].
Statistical analysis
Validity and reliability
Prior to the health status analyses, we tested the validity
and reliability of the scales used.
Validity was determined by means of Spearman’s rank
correlation tests among (1) the various SF-36 dimensions,
(2) the SF-36 dimension vitality and FAS and (3) the SF-36
domain body pain and painful myotonia. The reliability of
the SF-36 and FAS was estimated by calculating the
internal consistency (Cronbach’s a). A Cronbach’s a C 0.7
is considered as having a good reliability [22].
SF-36 values
The mean SF-36 domain and summary (PCS and MCS)
values for (1) chloride and sodium channelopathies, (2) the
fatigued and the non-fatigued group and (3) the painful and
painless myotonia group were compared with Dutch com-
munity scores (Student’s t test for independent groups) [1,
40].Inaddition,theSF-36domainscoresofthepatientswith
a chloride channelopathy were compared with those with a
sodium channelopathy, the fatigued patients were compared
with non-fatigued patients, and those patients with painful
myotonia were compared with their painless counterparts
(Student’s t test for independent groups) [1, 40].
Regression analysis
In both NDM groups linear regression analyses were per-
formed to determine which variable had the greatest impact
on the patients’ general health perception, PCS and MCS
(dependent variables). Age, gender, duration of symptoms,
frequency of myotonia, its pattern after repetitive contrac-
tions, myotonia severity and changes in severity, presence
of muscle weakness, presence of painful myotonia, severity
of the pain and the FAS were considered as explanatory
variables. Prior to the regression analyses, the distribution
pattern of the dependent variables were examined and, if
necessary, a transformation of the values was carried out to
obtain a normal distribution pattern. Univariate regression
analyses were conducted to reveal those independent vari-
ables that were related to dependent variables, separately.
This was achieved through a systematic evaluation of
constructed graphs with linear regression studies that
included a restricted cubic spline function on the indepen-
dent variable [14]. Subsequently, separate multivariate
linear regression analyses were performed for each depen-
dent variable, using the stepwise method including only the
independent variables that had shown P B 0.2 in the uni-
variate analyses. The strength of the association between
the dependent variable and the independent variables was
presented as R
2: the fraction of variance explained by the
independent variables from the regression model. All
analyses were performed using Stata 7.0 for Windows 2000
(Stata Corp., College Station, TX). A value of P\0.05 was
considered statistically signiﬁcant.
Results
Interview outcomes
Table 1 shows the basic characteristics of all NDM patients
obtained during the standardised interview. All patients
complained of myotonia, and the majority (96.9% in
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123chloride and 83.3% in sodium channelopathies) reported
daily complaints. All the patients with chloride channel-
opathies reported a decrease in myotonia after repetitive
contractions, which was 50.0% for the patients with a
sodium channelopathy, while the other half indicated an
increase (paradoxical myotonia). Although ten patients in
the chloride group and eight patients in the sodium group
used drugs to relieve myotonia before the study, both
groups claimed the severity of their myotonia had
increased since the onset of symptoms. Over half of all
patients with sodium channelopathies (56.7%) and about
30% (28.1%) of the patients with chloride channelopathies
characterised their myotonia as painful (v
2 = 5.18,
P = 0.02). Finally, 75% of the chloride channelopathies
versus 37% of the sodium channelopathies experienced
muscle weakness (v
2 = 9.26, P = 0.002).
Incidence painful myotonia
Twenty-six (41.9%) patients reported painful myotonia
with a mean NRS score of 6.1; 36 patients (58.1%)
reported painless myotonia. There was no relationship
between the presence of painful myotonia and gender
(v
2 = 0.287, P = 0.670) or between the presence of
painful myotonia and age (r =- 0.07, P = 0.60).
Fatigue rates by FAS
Based on their FAS scores, 33 (53.2%) patients were
classiﬁed as fatigued (FAS 27.2 ± 4.3) and 29 (46.8%) as
non-fatigued (FAS 16.2 ± 3.5). The FAS scores showed
no relationship with gender (r = 0.10, P = 0.440) or age
(r =- 0.05, P = 0.70).
Table 1 Basic characteristics
of all patients with non-
dystrophic myotonia (NDM),
for each subtype separately
Chloride
channelopathies
Sodium
channelopathies
P-value
(n = 32) (n = 30)
Gender, n (%) 0.131
Men 20 (62.5) 13 (43.3)
Women 12 (37.5) 17 (56.7)
Mean age in years (SD), range 45.7 (10.6), 23–60 38.7 (12.3), 19–68 0.019
Mean duration of symptoms (SD), range 36.1 (12.8), 9–57 34.3 (13.5), 6–68 0.599
Frequency of myotonic symptoms, n (%) 0.184
On a daily basis 31 (96.9) 25 (83.3)
Several times a week 1 (3.1) 4 (13.3)
Several times a year 0 (0.0) 1 (3.3)
Myotonia after repetitive movements, n (%) \0.001
Reduced (warm-up phenomenon) 32 (100) 15 (50.0)
Increased (paramyotonia) 0 (0) 15 (50.0)
Severity of myotonia (range: 1 = very mild, 10 = most
severe), n (%)
0.459
1–5 13 (40.6) 15 (50.0)
6–10 19 (59.4) 15 (50.0)
Changes in severity of myotonia, n (%) 0.541
Increasing 19 (59.4) 17 (56.7)
Stable 12 (37.7) 10 (33.3)
Decreasing 1 (3.1) 3 (10.0)
Muscle weakness, n (%) 0.002
Yes 24 (75.0) 11 (36.7)
No 8 (25.0) 19 (63.3)
Painful versus painless myotonia, n (%) 0.023
Painful myotonia 9 (28.1) 17 (56.7)
Painless myotonia 23 (71.9) 13 (43.3)
Severity of painful myotonia (range: 1 = very mild to
10 = most severe), n (%)
0.443
0 23 (71.9) 13 (43.3)
1–5 4 (12.5) 5 (16.7)
6–10 5 (15.6) 12 (40.0)
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123FAS and SF-36 validity and reliability scores
The matrix in Table 2 shows correlations among (1) the
various SF-36 domains, (2) the SF-36 domain vitality and
the FAS and (3) the SF-36 domain body pain and painful
myotonia for the two NDM groups separately. For most
SF-36 dimensions signiﬁcant correlations were obtained. In
both groups the SF-36 scores for vitality (higher scores
mean better vitality) correlated inversely with the FAS
scores (higher scores mean more fatigued), and the SF-36
scores for body pain (lower scores mean more pain) cor-
related inversely with painful myotonia (higher scores
mean more pain). Table 2 also shows the internal consis-
tencies for the SF-36. For all SF-36 dimensions, good
reliability scores (Cronbach’s alpha C 0.7) were obtained.
Cronbach’s alpha for the FAS was also good: 0.81 for
chloride and 0.90 for sodium channelopathies.
SF-36 outcomes
Chloride and sodium channelopathies
Compared with the Dutch community scores, the means
for the physically oriented SF-36 domains (physical
functioning, role functioning physical, vitality and general
health perception) and the corresponding PCS means were
notably lower (P B 0.01) in both NDM groups, indicative
of an inferior health status in the patients (Fig. 1a). The
means for the more mentally oriented SF-36 domains
(role functioning emotional, social functioning, mental
health and body pain) and MCS were comparable with
Dutch community scores, with social functioning in the
patients with sodium channelopathies (P = 0.048) as the
only exception. The body pain scores in the chloride
group were even signiﬁcantly higher (indicating less pain)
than in the Dutch community (P = 0.014). The SF-36
domain scores and the component scores did not differ
between the two NDM groups, with the exception of the
body pain scores, which were signiﬁcantly lower (indi-
cating more pain) in the sodium channelopathy group
(P = 0.032).
Painful and painless myotonia
Painful myotonia was associated with a signiﬁcant
decrease (P B 0.0001) of all SF-36 domain scores relative
to the Dutch community scores, except for the domains
role functioning emotional, mental health and MCS
(Fig. 1b). The values for role functioning emotional, social
functioning, body pain and mental health for the patients
that did not report painful myotonia were equal to or higher
than the Dutch community scores, whereas their means for
physical functioning, general health perception and PCS
were signiﬁcantly (P B 0.048) lower. The pain group
showed signiﬁcantly lower (P B 0.034) mean scores than
the non-pain group for role functioning physical, social
functioning, body pain, vitality, general health perception
and PCS.
Table 2 Content validity of the SF-36, the SF-36 domain vitality and FAS and the SF-36 domain body pain and painful myotonia for the two
NDM groups. It also shows the internal reliability of all SF-36 domains
PhF RFPh RFE SF BP MH Vit GHP PCS MCS
Validity studies (Spearman’s rank correlation coefﬁcients)
PhF Chl/Sod
RFPh 0.73/0.68 Chl/Sod
RFE NS/0.43 0.420.55 Chl/Sod
SF 0.38/0.39 0.43/0.56 NS/0.57 Chl/Sod
BP 0.38/0.49 0.50/0.59 NS/0.31 NS/0.59 Chl/Sod
MH NS/0.56 NS/0.67 0.40/0.52 0.54/NS NS/0.33 Chl/Sod
Vit 0.36/0.53 0.40/0.65 NS/0.42 0.52/0.63 0.31/0.63 0.47/0.59 Chl/Sod
GHP 0.31/0.50 0.46/0.67 NS/NS NS/0.65 0.38/0.80 NS/0.40 0.52/0.76 Chl/Sod
Chl/Sod Chl/Sod
FAS -0.85/-0.90
Painful myotonia -0.76/-0.67
Internal consistency (Cronbach’s alpha)
0.87/0.94 0.85/0.94 0.81/0.84 0.79/0.80 0.77/0.88 0.81/0.75 0.82/0.79 0.71/0.87 0.79/0.87 0.86/0.87
PhF physical functioning, RFPh role functioning physical, RFE role functioning emotional, SF social functioning, BP body pain (BP), MH
mental health, Vit vitality, GHP general health perception, PCS physical component summary, MCS mental component summary, FAS fatigue
assessment scale
Note All cited correlation scores were signiﬁcant (P\0.05), except the ones coded NS (not signiﬁcant)
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All SF-36 domain scores of the fatigued patients were
signiﬁcantly lower (P B 0.01) than the Dutch community
scores, except for the domains role functioning emotional,
mental health and body pain (Fig. 1c). The means for the
non-fatigued patients were equal or higher than the Dutch
community scores, apart from the mean for physical
functioning (P = 0.02). All SF-36 domain and summary
scores of the fatigued patients were substantially lower
(P B 0.01) than those found than their non-fatigued
counterparts (Fig. 1c).
Regression analysis
As the MCS scores (reﬂecting overall mental functioning)
for our NDM patients closely resembled the Dutch com-
munity scores, we restricted our regression analyses to
general health perception and PCS (see Fig. 1a). The
results of the analyses are shown in Fig. 2. In the chloride
group, 45% of the general health perception scores and
45% of the PCS scores were explained by the explanatory
variables. The variance proportions obtained in the sodium
group were higher: 77% for general health perception and
71% for PCS. Fatigue proved the strongest predictor of
general health perception (P B 0.01 for chloride and
P B 0.0001 for sodium channelopathies). In the sodium
group the pattern of myotonia (P = 0.001), gender
(P = 0.002), painful myotonia (P = 0.009) and duration of
symptoms (P = 0.019) also signiﬁcantly contributed to the
model. Painful myotonia was the strongest contributor to
the PCS score in the chloride channelopathies (P = 0.001),
in whom fatigue was also a signiﬁcant (P = 0.045) con-
tributor. In sodium channelopathies, painful myotonia
(P = 0.018), fatigue (P = 0.018) and pattern of myotonia
(P = 0.023) were also signiﬁcant contributors to the PCS
score.
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Fig. 1 a comparison of the mean values of the 36-item Short-Form
health survey proﬁles (SF-36) of the patients with NDM (n = 62) per
subtype and the mean values for the Dutch community. b The effect
of painful myotonia on the patients’ mean scores on the SF-36 versus
the reported means for the Dutch community. c The effect of fatigue
on the patients’ mean scores of the SF-36 scores versus the reported
mean for the Dutch community. NDM non-dystrophic myotonia. PhF
physical functioning; RFPh role functioning physical, RFE role
functioning emotional, SF social functioning, BP body pain, MH
mental health, Vit vitality, GHP general health perception, PCS
physical component summary, MCS mental component summary.
*P\0.05
Chloride-channelopathies Sodium-channelopathies
General-health-perception General-health-perception
Physical-component-summary Physical-component-summary
Gender and age
Duration of symptoms
Frequency of myotonia
Pattern of myotonia after repetitive contractions
Severity and change in severity of myotonia
Muscle weakness
Painful myotonia and severity of pain
Fatigue
Explanatory variables
R2 = 0.45  R2 = 0.77
R2= 0.71  R2 = 0.45 
Fatigue
strongest predictor 
Fatigue > Painful myotonia, 
gender and pattern of 
myotonia strongest predictors 
Pain > Fatigue 
strongest predictors 
Pain  and fatigue > pattern of myotonia 
strongest predictors
Fig. 2 Overview of the outcomes of the multivariate regression
analyses conducted to establish the variance and strongest predictor of
the general health perceptions and the physical component summary
in patients with non-dystrophic myotonia
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Despite the general notion that NDMs are benign diseases,
the current cross-sectional study demonstrates that the
symptoms of these patients do greatly impact their self-
reported health status. To our knowledge, ours is the ﬁrst
study to investigate health status in a large group of
genetically conﬁrmed NDM patients. The scores of the
NDM patients on the scale’s physically oriented domains
were substantially lower than the scores reported for the
Dutch community (Fig. 1a), reﬂecting a poorer clinical
condition for the patients [1, 38–40]. In addition, 42% of
the patients characterised their myotonia as painful and,
based on their FAS scores, 53% could be classiﬁed as being
fatigued. Furthermore, both painful myotonia and fatigue
were associated with a signiﬁcant decrease in almost all
SF-36 domain scores (Fig. 1b and c). Finally, our regres-
sion analyses revealed that in our sample fatigue was the
strongest predictor of low general health perceptions, while
painful myotonia best predicted low overall physical
functioning (Fig. 2).
The relatively low scores we found in our NDM patients
for the physical domains of the SF-36 closely resemble the
scores of other chronic diseases like type-II diabetes mel-
litus, myocardial infarction and angina pectoris with
hypertension, as reported in the USA population by the
constructors of the SF-36 [39]. In contrast, most of the
NDM patients’ scores on the scale’s mental domains and
its mental component score were quite similar to the Dutch
community scores [1, 38–40]. Studies of elderly patients
with chronic conditions, including various peripheral
neuropathies and eight chronic medical disorders, also
found lower scores on the SF-36 physical dimensions and
an unaltered mental state [16, 20, 30]. Presumably, these
patients are more preoccupied by changes in their physical
status, making them more focused on physical disabling
symptoms. Since NDM is a chronic and presumably
indolent, progressive disease, it is possible that patients
might learn to cope with their limitations. Indirect support
for this hypothesis is found in studies of more pronounced
progressive chronic illness, such as myotonic dystrophy,
ALS, Parkinson’s disease and multiple sclerosis. Here, the
SF-36 showed the patients’ emotional and mental states to
be more affected, although involvement of the central
nervous system could not be excluded [3, 23, 25, 31, 36].
The physical domains of the SF-36 of the NDM patients
with painful myotonia were substantially more affected
than those of the patients with painless myotonia. Pain had
earlier been observed to correlate with the physical
domains of the SF-36 in other slowly progressive neuro-
muscular diseases [2]. Fatigue resulted even in a substantial
decrease of all SF-36 domains. A negative impact of fati-
gue on health status was reported earlier in some chronic
neurological diseases and various muscular dystrophies
[11, 13, 15]. On the other hand, NDM patients without pain
or fatigue often had similar or even higher SF-36 scores
(better health condition) than the normal Dutch population.
This conﬁrms earlier assumptions that there indeed is a
group of NDM patients with only a minor or no impact on
their health status.
Since Aaronson et al. [1] studied the SF-36 domain
scores in different age classes of the Dutch population and
detected lower scores with increasing age, age differences
among the Dutch population, the NDM population and the
NDM subgroups should be discussed in the evaluation of
the results. However, since our data showed no correlation
between age and the domains of the SF-36 (data not
shown), including the physical-component summary and
the general-health perception, age differences do not
appear to play a role. Furthermore, the mean age of the
total NDM population (42.3 ± 11.9 years) is not signiﬁ-
cantly higher than the mean age of the Dutch population
studied by Aaronson (47.6 ± 18.0 years) [1]. Therefore,
the lower SF-36 scores of our NDM population could not
be caused by age differences. Also, the mean age of the two
NDM subgroups (painful myotonia versus painless myo-
tonia and fatigued versus non-fatigued) showed no
signiﬁcant differences. Only the NDM subgroup chloride
versus sodium channelopathies showed a signiﬁcant dif-
ference in age: chloride channelopathies were signiﬁcantly
older (Table 1). This is the only group in which we could
not pertinently rule out an inﬂuence of age differences.
As explained in the introduction, NDMs are not a single
disease. However, in this manuscript we only compared
chloride with sodium channelopathies. Of course, for more
thorough genotype-phenotype correlation studies, a further
subdivision should be made. Since the goal of this manu-
script was not to describe the different diseases as such but
the burden of the total NDM group in daily life and the fact
that we have only seen small groups for the different dis-
eases, which makes the groups possibly too small for
statistical analysis, we did not analyse more detailed
genotype-phenotype correlations.
Some permanent muscle weakness may be a feature of
NDM, especially in recessive myotonia congenita and some
sodium channelopathies. This could be a confounder.
However, since most patients with recessive myotonia
congenita experience transient paresis, chronic muscle
weakness is very difﬁcult to measure in this group. In the
sodium channelopathies all patients showed a maximum
MRC sum score (data not presented). Furthermore, none of
the patients showed such severe myotonia that muscles
became functionally weak. We therefore only used stand-
ardised interview parameters in the regression analyses. We
used different variables, including frequency of myotonia,
severity of myotonia, and muscle weakness, as explanatory
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123variables. None of these, in contrast to fatigue and pain,
were a signiﬁcant variable for the variance of the general
health perception or the physical component summary.
Prior to this study, no valid and reliable health status
measures had been obtained in patients with NDM. We
opted for the SF-36 because of its brevity, its extensive use
in clinical studies and its good psychometric properties [1,
38–40]. We selected the FAS to measure fatigue because of
its one-dimensionality, ease of use and proven validity and
reliability [7, 8, 21]. The scales’ good content validity and
reliability make them potentially useful endpoints for
future randomised clinical trials that evaluate the efﬁcacy
of and responsiveness to drug treatments such as
mexiletine.
Despite the solidity of our nationwide ﬁndings, it needs
to be noted that we did not evaluate the test-retest reli-
ability for the SF-36 and FAS, a psychometric omission
future research projects in this ﬁeld should correct. Fur-
thermore, ﬁve patients were unwilling to reduce and stop
their drug therapy, and nine patients had transportation
problems, including one patient who was severely handi-
capped. This means that there is a potential bias in this
study. Possibly some patients with more severe myotonia
have not been assessed. However, these patients may even
have a worse health status than the rest.
In summary, the current study shows that NDM sub-
stantially affects the patients’ physical health status, with
painful myotonia and fatigue being the strongest predictors
of the deﬁcits. Beside direct measurements of myotonia, it
is recommended that future intervention studies in patients
with NDM should also use the SF-36 and FAS to establish
the efﬁcacy of the therapeutic regimes under study.
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